Table 2.

Selected ongoing studies using the combination of ICIs and antiangiogenesis

Clinicaltrials.gov IDAntiangiogenesis drugICI drugCombination withCompetitor armTumor type
NCT03353831BevacizumabAtezolizumabChemotherapyBevacizumab+ chemotherapyOvarian cancer
NCT02997228BevacizumabAtezolizumabFOLFOXMSI-high colorectal cancer
NCT03063762BevacizumabAtezolizumabRO6874281RCC
NCT03434379BevacizumabAtezolizumabSorafenibHCC
NCT03175432BevacizumabAtezolizumabMelanoma brain mets
NCT03526432BevacizumabAtezolizumabEndometrial cancer
NCT03133390BevacizumabAtezolizumabCisplatin-ineligible urothelial cancer
NCT03024437BevacizumabAtezolizumabEntinostatRCC
NCT03556839BevacizumabAtezolizumabCervical cancer
NCT03038100BevacizumabAtezolizumabPaclitaxel, carboplatinOvarian, fallopian tube, or primary peritoneal cancer
NCT03181100BevacizumabAtezolizumabChemotherapyAnaplastic and poorly differentiated thyroid carcinomas
NCT03395899BevacizumabAtezolizumabNeoadjuvant estrogen receptor–positive breast cancer
NCT03555149BevacizumabAtezolizumabRegorafenib, imprime PGG, or isatuximabMicrosatellite-stable colorectal cancer
NCT03280563BevacizumabAtezolizumabEnitinostat, exemestane, fulvestrant, ipatasertib, or tamoxifenHR+HER-2+ breast cancer
NCT03424005BevacizumabAtezolizumabIpatasertib, SGN-LIV1A, bevacizumab, cobimetinib, or chemotherapyTNBC
NCT03193190BevacizumabAtezolizumabChemotherapyPancreatic cancer
NCT02336165BevacizumabDurvalumabGlioblastoma
NCT02337491BevacizumabPembrolizumabPembrolizumabGlioblastoma
NCT02496208CabozantinibNivolumab+ ipilimumabCabozantinib + nivolumabGenitourinary tumors
NCT03367741CabozantinibNivolumabEndometrial cancer
NCT03635892CabozantinibNivolumabNonclear RCC
NCT03316586CabozantinibNivolumabTNBC
NCT03149822CabozantinibPembrolizumabRCC
NCT03468218CabozantinibPembrolizumabHead and neck cancer
NCT03534804CabozantinibPembrolizumabUrothelial carcinoma
NCT01658878CabozantinibNivolumab ± ipilimumabNivolumab, nivolumab + ipilimumab, sorafenibHCC
NCT03291314AxitinibAvelumabGlioblastoma
NCT03289533AxitinibAvelumabHCC
NCT03472560AxitinibAvelumabNSCLC and urothelial cancer
NCT03172754AxitinibNivolumabRCC
NCT03736330AxitinibPembrolizumabD-CIKRCC
NCT02636725AxitinibPembrolizumabSoft tissue sarcomas
NCT02853331AxitinibPembrolizumabSunitinibRCC
NCT02684006AxitinibAvelumabSunitinibRCC
NCT01472081PazopanibNivolumabNivolumab +RCC
SunitinibNivolumabipilimumab
NCT02014636PazopanibPembrolizumabRCC
NCT03277924SunitinibNivolumabSoft tissue and bone sarcomas
NCT03211416SorafenibPembrolizumabHCC
NCT03439891SorafenibNivolumabHCC
NCT03239145Trebananib (Ang-2 inhibitor)PembrolizumabMelanoma, RCC, ovarian cancer, colorectal cancer
NCT01688206Vanucizumab (VEGF-A and Ang-2)AtezolizumabSolid tumors
NCT02665416Vanucizumab (VEGF-A and Ang-2)Selicrelumab (CD40 agonist)Solid tumors
  • Abbreviations: HR, hormone receptor; MSI, microsatellite instability; TNBC, triple-negative breast cancer.